ALNUJEV
DEAD

Serial Number

98064688

Owner

Bristol-Myers Squibb Company

Attorney

Marilyn F. Kelly

Filing Date

Jun 29, 2023

Add to watchlist:

No watchlists yet
View on USPTO

ALNUJEV Trademark

Serial Number: 98064688

ALNUJEV is a trademark filed by Bristol-Myers Squibb Company on June 29, 2023. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

Bristol-Myers Squibb Company (57 trademarks)

Route 206 & Province Line Road
Princeton, NJ 08543

Entity Type: 03

Trademark Details

Filing Date

June 29, 2023

Registration Date

Not Registered

Published for Opposition

June 3, 2025

Goods & Services

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
May 4, 2026 MAB6
ABANDONMENT - NO USE STATEMENT FILED
May 4, 2026 ABN6
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Sep 30, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 3, 2025 NPUB
PUBLISHED FOR OPPOSITION
Jun 3, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 28, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 2, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
May 2, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
May 2, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
May 2, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
May 2, 2025 CNEA
NOTIFICATION OF FINAL REFUSAL EMAILED
Jan 11, 2025 GNFN
FINAL REFUSAL E-MAILED
Jan 11, 2025 GNFR
FINAL REFUSAL WRITTEN
Jan 11, 2025 CNFR
ASSIGNED TO EXAMINER
Dec 10, 2024 DOCK
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 2, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 2, 2024 CRFA
ASSIGNED TO LIE
Oct 1, 2024 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 10, 2024 TROA
NOTICE OF REVIVAL - E-MAILED
Jun 10, 2024 NREV
PETITION TO REVIVE-GRANTED
Jun 10, 2024 PETG
TEAS PETITION TO REVIVE RECEIVED
Jun 10, 2024 PROA
ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Jun 5, 2024 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Jun 5, 2024 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 14, 2024 GNRN
NON-FINAL ACTION E-MAILED
Feb 14, 2024 GNRT
NON-FINAL ACTION WRITTEN
Feb 14, 2024 CNRT
ASSIGNED TO EXAMINER
Feb 7, 2024 DOCK
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 2, 2023 TCCA
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 1, 2023 NWOS
NEW APPLICATION ENTERED
Jul 3, 2023 NWAP